See more : Comcast Corporation (CMCSA) Income Statement Analysis – Financial Results
Complete financial analysis of Ind-Swift Laboratories Limited (INDSWFTLAB.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ind-Swift Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shyam Telecom Limited (SHYAMTEL.NS) Income Statement Analysis – Financial Results
- MEDBRIGHT AI INVTS INC (MBAIF) Income Statement Analysis – Financial Results
- DKSH Holding AG (DKSH.SW) Income Statement Analysis – Financial Results
- Perception Capital Corp. II (PCCT) Income Statement Analysis – Financial Results
- Consolidated Finvest & Holdings Limited (CONSOFINVT.NS) Income Statement Analysis – Financial Results
Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.indswiftlabs.com
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.81B | 12.07B | 10.39B | 8.91B | 7.80B | 7.57B | 7.63B | 7.16B | 6.53B | 6.60B | 9.65B | 11.36B | 14.09B | 10.37B | 7.85B | 5.90B | 4.58B | 3.50B |
| Cost of Revenue | 6.61B | 7.67B | 6.29B | 5.16B | 4.70B | 4.74B | 4.72B | 4.71B | 4.06B | 4.65B | 8.08B | 9.59B | 11.53B | 7.73B | 6.08B | 4.25B | 3.33B | 2.55B |
| Gross Profit | 6.19B | 4.40B | 4.10B | 3.75B | 3.10B | 2.83B | 2.91B | 2.45B | 2.48B | 1.96B | 1.57B | 1.77B | 2.56B | 2.64B | 1.77B | 1.65B | 1.25B | 953.41M |
| Gross Profit Ratio | 48.36% | 36.48% | 39.43% | 42.08% | 39.76% | 37.37% | 38.14% | 34.25% | 37.92% | 29.62% | 16.23% | 15.62% | 18.15% | 25.48% | 22.57% | 27.91% | 27.32% | 27.22% |
| Research & Development | 355.17M | 425.74M | 327.16M | 330.13M | 59.16M | 5.21M | 3.10M | 1.92M | 4.22M | 3.06M | 77.94M | 76.04M | 6.73M | 56.84M | 52.27M | 49.38M | 36.84M | 54.45M |
| General & Administrative | 1.54B | 205.16M | 204.06M | 159.45M | 173.19M | 173.41M | 168.13M | 125.81M | 100.73M | 82.69M | 118.82M | 125.26M | 110.22M | 715.77M | 181.00M | 159.49M | 141.29M | 131.08M |
| Selling & Marketing | 45.55M | 430.61M | 440.01M | 321.66M | 248.72M | 251.96M | 314.97M | 323.43M | 320.04M | 302.32M | 167.48M | 288.68M | 206.18M | 182.15M | 167.55M | 118.59M | 70.72M | 73.95M |
| SG&A | 1.58B | 635.77M | 644.07M | 481.12M | 421.91M | 425.38M | 483.11M | 449.23M | 420.77M | 385.01M | 286.30M | 413.94M | 316.40M | 715.77M | 348.55M | 278.08M | 212.01M | 205.03M |
| Other Expenses | 0.00 | 9.17M | 139.96M | 34.80M | -5.96M | 29.12M | 1.40M | 39.41M | 26.10M | 13.18M | 19.74M | 108.60M | 167.05M | 586.37M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.94B | 2.59B | 3.17B | 2.64B | 2.37B | 2.38B | 2.29B | 2.11B | 2.14B | 1.70B | 1.55B | 1.57B | 1.08B | 1.22B | 777.13M | 649.91M | 517.69M | 442.39M |
| Cost & Expenses | 8.55B | 10.26B | 9.46B | 7.80B | 7.07B | 7.12B | 7.01B | 6.82B | 6.20B | 6.35B | 9.63B | 11.15B | 12.61B | 8.95B | 6.86B | 4.90B | 3.84B | 2.99B |
| Interest Income | 183.71M | 58.72M | 5.62M | 5.13M | 13.64M | 27.07M | 38.46M | 9.22M | 7.11M | 35.56M | 34.46M | 36.14M | 127.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 511.04M | 863.93M | 914.53M | 933.53M | 1.02B | 839.60M | 269.32M | 746.97M | 907.52M | 993.06M | 873.21M | 727.37M | 495.42M | 558.97M | 510.62M | 469.55M | 292.72M | 258.76M |
| Depreciation & Amortization | 533.03M | 570.80M | 1.31B | 872.92M | 898.28M | 1.04B | 866.16M | 882.56M | 847.49M | 842.90M | 657.66M | 543.51M | 398.61M | 409.30M | 419.00M | 294.09M | 199.10M | 123.06M |
| EBITDA | 6.86B | 2.36B | 2.23B | 1.98B | 1.78B | 1.49B | 1.49B | 1.23B | 1.18B | 582.26M | 110.24M | 82.46M | 1.76B | 1.86B | 1.43B | 1.26B | 884.51M | 627.27M |
| EBITDA Ratio | 53.57% | 21.37% | 23.94% | 22.29% | 22.15% | 20.46% | 19.86% | 15.78% | 16.72% | 14.10% | 4.55% | 1.98% | 12.51% | 17.92% | 18.90% | 21.83% | 20.36% | 17.91% |
| Operating Income | 4.42B | 1.74B | 785.09M | 971.52M | 548.04M | 221.12M | 478.09M | -583.59M | -853.92M | -1.45B | -1.44B | -1.30B | 843.46M | 1.45B | 1.07B | 994.42M | 732.83M | 504.20M |
| Operating Income Ratio | 34.51% | 14.37% | 7.56% | 10.90% | 7.03% | 2.92% | 6.27% | -8.15% | -13.07% | -21.90% | -14.92% | -11.42% | 5.99% | 13.97% | 13.56% | 16.85% | 16.01% | 14.40% |
| Total Other Income/Expenses | 1.40B | -2.91B | -659.77M | -791.43M | -928.97M | 51.49M | -258.83M | -731.08M | -1.05B | -1.48B | -1.35B | -1.40B | -518.06M | -531.57M | -491.05M | -497.66M | -340.14M | -265.57M |
| Income Before Tax | 5.82B | 865.21M | 125.32M | 180.09M | -197.71M | 496.77M | 359.86M | -553.02M | -827.81M | -1.43B | -1.42B | -1.19B | 865.47M | 889.88M | 504.21M | 499.61M | 392.69M | 245.45M |
| Income Before Tax Ratio | 45.42% | 7.17% | 1.21% | 2.02% | -2.54% | 6.57% | 4.72% | -7.72% | -12.67% | -21.70% | -14.72% | -10.46% | 6.14% | 8.58% | 6.42% | 8.47% | 8.58% | 7.01% |
| Income Tax Expense | 1.60B | 386.90M | 146.81M | 211.56M | 14.17M | 207.31M | 140.11M | -161.68M | -240.94M | -239.83M | -200.51M | -9.42M | -26.14M | -899.36M | -59.65M | 95.69M | 78.48M | 63.06M |
| Net Income | 4.21B | 475.97M | -21.49M | -31.47M | -211.88M | 289.46M | 219.76M | -391.34M | -586.88M | -1.19B | -1.22B | -1.18B | 891.61M | 894.62M | 563.86M | 403.92M | 314.21M | 182.39M |
| Net Income Ratio | 32.86% | 3.94% | -0.21% | -0.35% | -2.72% | 3.83% | 2.88% | -5.46% | -8.98% | -18.07% | -12.64% | -10.38% | 6.33% | 8.63% | 7.18% | 6.84% | 6.86% | 5.21% |
| EPS | 71.24 | 8.06 | -0.36 | -0.53 | -4.28 | 5.30 | 4.88 | -9.20 | -14.33 | -29.14 | -29.79 | -30.07 | 24.86 | 29.76 | 20.86 | 16.22 | 13.63 | 8.21 |
| EPS Diluted | 71.24 | 8.06 | -0.36 | -0.53 | -4.28 | 5.30 | 4.88 | -9.20 | -14.33 | -29.14 | -29.79 | -29.82 | 23.98 | 27.57 | 20.19 | 15.31 | 13.43 | 8.12 |
| Weighted Avg Shares Out | 59.09M | 59.09M | 59.09M | 59.09M | 49.46M | 54.64M | 45.07M | 42.55M | 40.96M | 40.96M | 40.96M | 39.20M | 35.87M | 29.44M | 27.03M | 24.90M | 23.05M | 22.20M |
| Weighted Avg Shares Out (Dil) | 59.09M | 59.09M | 59.09M | 59.09M | 49.46M | 54.64M | 45.07M | 42.55M | 40.96M | 40.96M | 40.96M | 39.53M | 37.19M | 31.78M | 27.92M | 26.38M | 23.39M | 22.45M |
Source: https://incomestatements.info
Category: Stock Reports